CN104250223A - 阿扎那韦氢溴酸盐及其制备和应用 - Google Patents
阿扎那韦氢溴酸盐及其制备和应用 Download PDFInfo
- Publication number
- CN104250223A CN104250223A CN201310269562.1A CN201310269562A CN104250223A CN 104250223 A CN104250223 A CN 104250223A CN 201310269562 A CN201310269562 A CN 201310269562A CN 104250223 A CN104250223 A CN 104250223A
- Authority
- CN
- China
- Prior art keywords
- reyataz
- hydrobromate
- crystal formation
- atazanavir
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310269562.1A CN104250223B (zh) | 2013-06-28 | 2013-06-28 | 阿扎那韦氢溴酸盐及其制备和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310269562.1A CN104250223B (zh) | 2013-06-28 | 2013-06-28 | 阿扎那韦氢溴酸盐及其制备和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104250223A true CN104250223A (zh) | 2014-12-31 |
CN104250223B CN104250223B (zh) | 2017-04-12 |
Family
ID=52185505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310269562.1A Active CN104250223B (zh) | 2013-06-28 | 2013-06-28 | 阿扎那韦氢溴酸盐及其制备和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104250223B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109251165A (zh) * | 2018-10-02 | 2019-01-22 | 黄胜利 | 阿扎那韦达二4-氨基苯磺酸盐及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
US6087383A (en) * | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
-
2013
- 2013-06-28 CN CN201310269562.1A patent/CN104250223B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
US6087383A (en) * | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
CN1283188A (zh) * | 1998-01-20 | 2001-02-07 | 布里斯托尔-米尔斯·斯奎布公司 | Hiv蛋白酶抑制剂的硫酸氢盐 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109251165A (zh) * | 2018-10-02 | 2019-01-22 | 黄胜利 | 阿扎那韦达二4-氨基苯磺酸盐及其制备方法 |
CN109251165B (zh) * | 2018-10-02 | 2022-09-23 | 国药集团川抗制药有限公司 | 阿扎那韦达二4-氨基苯磺酸盐及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104250223B (zh) | 2017-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104822680B (zh) | 咪唑并吡啶化合物 | |
CN104109149B (zh) | 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物 | |
CN101184734B (zh) | 治疗细胞增殖紊乱的化合物和方法 | |
JP6505013B2 (ja) | スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用 | |
NO335103B1 (no) | Forbindelse, farmasøytisk preparat inneholdende forbindelsen, anvendelse av forbindelsen samt fremgangsmåte for fremstilling derav | |
JP7323603B2 (ja) | 三環式縮合フラン置換ピペリジンジオン系化合物 | |
JP6158811B2 (ja) | 4−[5−(ピリジン−4−イル)−1h−1,2,4−トリアゾール−3−イル]ピリジン−2−カルボニトリルの結晶多形およびその製造方法 | |
CN105814067A (zh) | 作为钠通道调节剂的吡啶酮酰胺的前药 | |
CN101675040A (zh) | 作为钠通道调节剂的2-吡啶甲酰胺衍生物 | |
AU2014295143B2 (en) | Salts of Dasatinib in amorphous form | |
CN104230793A (zh) | 调控激酶级联的组合物以及方法 | |
AU2017287553A1 (en) | Imidazopyrazinamine phenyl derivative and use thereof | |
CA2570942A1 (en) | Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof, and use of the same as medicament | |
SA109300090B1 (ar) | صور متبلرة جديدة من 4- [4- (2- أدامنتيل كربامويل) -5- ثلاثي- بيوتيل – بيرازول -1- يل] حمض بنزويك 471 | |
JPH05178840A (ja) | ピリミジンの新誘導体、それらの製造法、得られる中間体、それらの薬剤としての使用及びそれらを含有する製薬組成物 | |
CN103450152A (zh) | 基于吲唑、吲哚或氮杂吲唑、氮杂吲哚的双芳基脲类结构抗肿瘤药物 | |
AU2016239028B2 (en) | P-toluenesulfonate for MEK kinase inhibitor, and crystal form thereof and preparation method therefor | |
MX2015002310A (es) | Nuevas amidas de fenil-piridina/pirazina para el tratamiento de cancer. | |
US9453011B2 (en) | Crystal form of dabrafenib mesylate and preparation method thereof | |
CN106573888A (zh) | 维莫德吉和所选共晶形成剂或溶剂的多组分晶体 | |
JP2006520780A (ja) | アンドロゲン受容体アンタゴニストとしてのキノリンおよびクロメンの6−スルホンアミド誘導体 | |
CN104610195A (zh) | 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 | |
TW202246254A (zh) | 聯芳組成物和調控激酶級聯之方法 | |
CN104250223A (zh) | 阿扎那韦氢溴酸盐及其制备和应用 | |
CN104250224A (zh) | 阿扎那韦富马酸盐及其制备和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181213 Address after: 277500 No. 88 Weizhi Avenue, Tengzhou Biomedical Industry Base, Zaozhuang City, Shandong Province Patentee after: VIWIT PHARMACEUTICAL Co.,Ltd. Address before: Room 404, Building No. 2, 500 Caobao Road, Xuhui District, Shanghai, 2003 Patentee before: SHANGHAI VIWIT PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: No. 88, Weizhi Avenue, Tengzhou biomedical industrial park, Zaozhuang, Shandong 277500 Patentee after: Weizhi Pharmaceutical Co.,Ltd. Address before: 277500 88, Wei Zhi Avenue, biological medicine industry base, Tengzhou City, Zaozhuang, Shandong. Patentee before: VIWIT PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: No. 88, Weizhi Avenue, biomedical industrial park, Tengzhou City, Zaozhuang City, Shandong Province, 277500 Patentee after: Weizhi Pharmaceutical Co.,Ltd. Address before: No. 88, Weizhi Avenue, biomedical industrial park, Tengzhou City, Zaozhuang City, Shandong Province, 277500 Patentee before: Weizhi Pharmaceutical Co.,Ltd. |